Morgan Stanley Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $59
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit has maintained an Overweight rating on Halozyme Therapeutics (NASDAQ:HALO) but reduced the price target from $61 to $59.

December 26, 2023 | 3:46 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley has maintained its Overweight rating on Halozyme Therapeutics but lowered the price target from $61 to $59.
While the reduction in price target could suggest a slightly less bullish outlook, the maintenance of an Overweight rating indicates that Morgan Stanley still sees positive potential in HALO. The impact on the stock price may be neutral to slightly negative in the short term as the market digests the mixed signals of a lower price target with a continued positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100